FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation
FDA Approves Byfavo (remimazolam injection) for the Induction and Maintenance of Procedural Sedation Print this page Dublin, Ireland – 2 July 2020: Cosmo Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has approved Byfavo (remimazolam injection) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or… Read More »